Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.73 |
| ▸ | PPARA | Q07869 | 13/20 | 0.73 |
| ▸ | PPARD | Q03181 | 9/20 | 0.73 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | POLQ | O75417 | 3/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575267 | 0.87 | PPARA (0.57) | PPARGPPARAPPARDPOLQ | |
| SCHEMBL18644831 | 0.84 | PPARA (1.00) | PPARGPPARAPPARDPOLQ | |
| SCHEMBL14277966 | 0.83 | PPARA (0.68) | PPARGPPARAPPARD | |
| SCHEMBL4576153 | 0.79 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL4575631 | 0.79 | PPARA (0.54) | PPARGPPARAPPARDPOLQ | |
| SCHEMBL4575324 | 0.79 | PPARA (0.52) | PPARGPPARAPPARD | |
| SCHEMBL4575332 | 0.78 | PPARA (0.51) | PPARGPPARAPPARD | |
| SCHEMBL4576038 | 0.78 | PPARA (0.51) | PPARGPPARAPPARD | |
| SCHEMBL4574820 | 0.76 | PPARA (0.59) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL4575961 | 0.76 | PPARA (0.57) | PPARGPPARAPPARDCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.